Hang Quach
0000-0002-4796-3352
Publication & Citation Trends
Publications
0 total
Efficacy and Safety of Belantamab Mafodotin with Bortezomib Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: the DREAMM-6 Arm B Trial.
Cited by 0
Semantic Scholar
Treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group
Cited by 0
Semantic Scholar
Deep responses and durable outcomes in patients treated with belantamab mafodotin plus pomalidomide and dexamethasone from long-term follow-up of the Phase 3 dreamm-8 study
Cited by 0
Semantic Scholar
An immune-therapeutic salvage strategy for ‘functional’ high-risk (FHR) multiple myeloma (MM) incorporating iberdomide, isatuximab, and dexamethasone – the IBIS study amarc 20-01.
Cited by 0
Semantic Scholar
Etentamig plus pomalidomide-dexamethasone combination therapy in relapsed or refractory multiple myeloma: A phase 1b dose-escalation and safety expansion study
Cited by 0
Semantic Scholar
POSTER: MM-1037 Elranatamab (ELRA) in Combination With Daratumumab and Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible for Transplant: Initial Results From MagnetisMM-6 Part 1
Cited by 0
Semantic Scholar
EXCALIBER-RRMM: a phase III trial of iberdomide, daratumumab, and dexamethasone in relapsed/refractory multiple myeloma
Cited by 2
Semantic Scholar
Subcutaneous daratumumab (Dara) + bortezomib/lenalidomide/dexamethasone (VRd) with Dara + lenalidomide (DR) maintenance in transplant-eligible (TE) patients with newly diagnosed multiple myeloma (NDMM): Analysis of sustained minimal residual disease negativity in the phase 3 PERSEUS trial.
Cited by 5
Semantic Scholar
Research Topics
Multiple Myeloma Research and Treatments
(381)
Protein Degradation and Inhibitors
(163)
Peptidase Inhibition and Analysis
(85)
Chronic Lymphocytic Leukemia Research
(61)
Cancer Treatment and Pharmacology
(57)
Affiliations
Ontario Institute for Cancer Research
St. Vincent's Birmingham
Memorial Sloan Kettering Cancer Center
University College London Hospitals NHS Foundation Trust
Box Hill Hospital